CMMB

Chemomab Therapeutics
CMMB

$1
2.15%
 

About: Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Employees: 20

0
Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

45% more capital invested

Capital invested by funds: $1.43M [Q4 2023] → $2.07M (+$639K) [Q1 2024]

0.34% less ownership

Funds ownership: 1.27% [Q4 2023] → 0.94% (-0.34%) [Q1 2024]

13% less funds holding

Funds holding: 16 [Q4 2023] → 14 (-2) [Q1 2024]

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$4
300%
upside
Avg. target
$5
401%
upside
High target
$6
501%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Maxim Group
Michael Okunewitch
300%upside
$4
Buy
Initiated
13 May 2024
Oppenheimer
Jeff Jones
501%upside
$6
Outperform
Upgraded
6 May 2024

Financial journalist opinion